Yu Chen1, Zeng-Qing Guo2, Chun-Mei Shi3, Zhi-Feng Zhou4, Yun-Bin Ye5, Qiang Chen3. 1. Department of Medical Oncology, The Union Clinical Medical College of Fujian Medical University Fuzhou, Fujian Province, People's Republic of China. 2. Fujian Key Laboratory of Translational Cancer Medicine Fuzhou, Fujian Province, People's Republic of China ; Department of Medical Oncology, Fujian Provincial Cancer Hospital ,Fujian Medical University Teaching Hospital Fuzhou, Fujian Province, People's Republic of China. 3. Department of Medical Oncology, The Union Clinical Medical College of Fujian Medical University Fuzhou, Fujian Province, People's Republic of China ; Fujian Key Laboratory of Translational Cancer Medicine Fuzhou, Fujian Province, People's Republic of China. 4. Fujian Key Laboratory of Translational Cancer Medicine Fuzhou, Fujian Province, People's Republic of China ; Laboratory of Immuno-Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital Fuzhou, Fujian Province, People's Republic of China. 5. The School of Basic Medical Sciences Fujian Medical University Fuzhou, Fujian Province, People's Republic of China ; Fujian Key Laboratory of Translational Cancer Medicine Fuzhou, Fujian Province, People's Republic of China.
Abstract
BACKGROUND AND AIMS: It remains a challenge to prevent the local recurrence or distant metastasis of gastric carcinoma after D2 gastrectomy. Cytokine-induced killer (CIK) cells have shown promising activity against solid tumors in vitro and in vivo. We investigated the effect of adjuvant chemotherapy combined with autologous CIK therapy after D2 gastrectomy compared with adjuvant chemotherapy alone after D2 gastrectomy in patients with stage II-III gastric cancer. METHODS: From January 2009 to December 2011, 226 patients with stage II-III gastric cancer who had had curative D2 gastrectomy were enrolled. Eighty-nine patients (CIK group) received adjuvant chemotherapy combining with autologous CIK therapy and 137 patients (control group) received adjuvant chemotherapy alone. Disease-free survival (DFS) and overall survival (OS) were evaluated. RESULTS: Patients in the CIK group had longer DFS and OS than patients in the control group (DFS 41.0 months vs. 32.0 months, OS 45.0 months vs. 44.0 months, by log-rank test P = 0.006 and P = 0.028, respectively). In subgroup analysis, no significant differences in DFS and OS were observed between the two groups for the patients with stages II disease. Patients with stage III disease in the CIK group had longer median DFS and OS than patients in the control group (P = 0.031 and P = 0.038, respectively). In multivariate analysis, the stage and the interaction of stage and CIK therapy were independent prognostic factors for DFS and OS. CONCLUSIONS: The data suggest that adjuvant chemotherapy combined with autologous CIK therapy can improve prognosis for gastric carcinoma patients after D2 gastrectomy, especially for the patients with stage III disease.
BACKGROUND AND AIMS: It remains a challenge to prevent the local recurrence or distant metastasis of gastric carcinoma after D2 gastrectomy. Cytokine-induced killer (CIK) cells have shown promising activity against solid tumors in vitro and in vivo. We investigated the effect of adjuvant chemotherapy combined with autologous CIK therapy after D2 gastrectomy compared with adjuvant chemotherapy alone after D2 gastrectomy in patients with stage II-III gastric cancer. METHODS: From January 2009 to December 2011, 226 patients with stage II-III gastric cancer who had had curative D2 gastrectomy were enrolled. Eighty-nine patients (CIK group) received adjuvant chemotherapy combining with autologous CIK therapy and 137 patients (control group) received adjuvant chemotherapy alone. Disease-free survival (DFS) and overall survival (OS) were evaluated. RESULTS:Patients in the CIK group had longer DFS and OS than patients in the control group (DFS 41.0 months vs. 32.0 months, OS 45.0 months vs. 44.0 months, by log-rank test P = 0.006 and P = 0.028, respectively). In subgroup analysis, no significant differences in DFS and OS were observed between the two groups for the patients with stages II disease. Patients with stage III disease in the CIK group had longer median DFS and OS than patients in the control group (P = 0.031 and P = 0.038, respectively). In multivariate analysis, the stage and the interaction of stage and CIK therapy were independent prognostic factors for DFS and OS. CONCLUSIONS: The data suggest that adjuvant chemotherapy combined with autologous CIK therapy can improve prognosis for gastric carcinomapatients after D2 gastrectomy, especially for the patients with stage III disease.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: I G Schmidt-Wolf; P Lefterova; B A Mehta; L P Fernandez; D Huhn; K G Blume; I L Weissman; R S Negrin Journal: Exp Hematol Date: 1993-12 Impact factor: 3.084
Authors: Hong-Jun Fei; Li-Dong Zu; Jun Wu; Xiao-Shu Jiang; Jing-Long Wang; Y Eugene Chin; Guo-Hui Fu Journal: Am J Cancer Res Date: 2016-12-01 Impact factor: 6.166
Authors: Yangjin Kim; Ji Young Yoo; Tae Jin Lee; Joseph Liu; Jianhua Yu; Michael A Caligiuri; Balveen Kaur; Avner Friedman Journal: Proc Natl Acad Sci U S A Date: 2018-04-23 Impact factor: 11.205
Authors: Magdalena Tyczyńska; Paweł Kędzierawski; Kaja Karakuła; Jacek Januszewski; Krzysztof Kozak; Monika Sitarz; Alicja Forma Journal: J Gastrointest Cancer Date: 2021-03-24
Authors: Umme Hani; Riyaz Ali M Osmani; Sabina Yasmin; B H Jaswanth Gowda; Hissana Ather; Mohammad Yousuf Ansari; Ayesha Siddiqua; Mohammed Ghazwani; Adel Al Fatease; Ali H Alamri; Mohamed Rahamathulla; M Yasmin Begum; Shadma Wahab Journal: Pharmaceutics Date: 2022-07-29 Impact factor: 6.525